ILT3 polypeptides and uses thereof
This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
1. A method of treating, delaying the onset of, or inhibiting graft versus host disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a soluble polypeptide comprising the extracellular domain of human ILT3.
2. The method of claim 1 , wherein the polypeptide is administered subcutaneously, intradermally, intravenously, or intraperitoneally.
3. The method of claim 1 , wherein the polypeptide further comprises an Fc portion of an immunoglobulin, wherein the Fc portion of an immunoglobulin comprises a function-enhancing mutation.
4. The method of claim 3 , wherein the function-enhancing mutation in the Fc portion inhibits binding of the Fc portion to an Fc receptor.
5. The method of claim 1 , wherein the Fc portion of an immunoglobulin is a Fc portion of IgG1.
6. The method of claim 5 , wherein the IgG1 is a human IgG1.
7. The method of claim 4 , wherein the function-enhancing mutation in the Fc portion comprises an Asn->Gln point mutation at the N-linked glycosylation site of human IgG1.
8. The method of claim 1 , wherein the polypeptide is administered to the subject at onset of graft rejection.
9. The method of claim 1 , wherein the subject is a mammal.
10. The method of claim 9 , wherein the subject is a human.
11. The method of claim 1 , further comprising administering to the subject an effective amount of another immunosuppressive agent.